PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of viruLink to Publisher's site
 
Virulence. 2013 August 15; 4(6): 489–493.
Published online 2013 August 2. doi:  10.4161/viru.25952
PMCID: PMC5359727

Increased virulence of neuraminidase inhibitor-resistant pandemic H1N1 virus in mice

Potential emergence of drug-resistant and virulent variants

Abstract

Pandemic H1N1 2009 (A[H1N1]pdm09) variants associated with oseltamivir resistance have emerged with a histidine-to-tyrosine substitution in the neuraminidase(NA) at position 274 (H274Y). To determine whether the H274Y variant has increased virulence potential, A(H1N1)pdm09 virus, with or without the H274Y mutation, was adapted by serial lung-to-lung passages in mice. The mouse-adapted H274Y (maCA04H274Y) variants showed increased growth properties and virulence in vitro and in vivo while maintaining high NA inhibitor resistance. Interestingly, most maCA04H274Y and maCA04 viruses acquired common mutations in HA (S183P and D222G) and NP (D101G), while only maCA04H274Y viruses had consensus additional K153E mutation in the HA gene, suggesting a potential association with the H274Y substitution. Collectively, our findings highlight the potential emergence of A(H1N1)pdm09 drug-resistant variants with increased virulence and the need for rapid development of novel antiviral drugs.

Keywords: pandemic influenza, drug resistance, mouse adaptation, virulence, neuraminidase

The pandemic H1N1 2009 (A[H1N1]pdm09) virus has begun to act as a seasonal influenza since it caused an influenza outbreak in 2009. Before the pandemic, especially during the 2007–2008 season, most seasonal H1N1 viruses had a neuraminidase (NA) gene with a substitution of tyrosine for histidine at residue 274 (H274Y, N2 numbering) which confers resistance to oseltamivir (OS),1,2 the most widely used drug for clinical therapy of influenza-infected patients, albeit mostly with compromised viral fitness.3,4 Fortunately, the A(H1N1)pdm09 virus remained sensitive to neuraminidase inhibitors (NAIs) such as OS. However, the widespread use of NAIs to treat patients that are believed to be infected with A(H1N1)pdm09 in many countries led the virus to evolve into drug-resistant variants.5 Furthermore, unlike previous seasonal H1N1 drug-resistant variants of A(H1N1)pdm09 retained comparable viral fitness in pathogenesis and transmissibility to those of their OS-sensitive counterparts.6,7

A(H1N1)pdm09 virus has exhibited remarkable transmissibility among humans and even reverse-zoonotic transmission, such as to pigs and turkeys,8,9 but the pathogenicity of the virus was milder than that of the pandemic virus in 1918. However, several studies have shown increased pathogenesis of A(H1N1)pdm09 in new host species through mouse adaptation and molecular-based substitutions related to enhanced virulence,10-12 although the tested viruses still remained NAI-sensitive. Of note, in two of these studies, the mouse-adapted variants also showed enhanced fitness in ferrets,11,12 suggesting mice are a relevant model for such studies.

The virulence potential of A(H1N1)pdm09 variants with drug-resistance mutations in the NA gene has been poorly understood. Increasing numbers of cases of oseltamivir (OS)-resistant variants, especially associated with the H274Y mutation, have been reported to the World Health Organization,13 implicating a potential threat of virulent and drug-resistant variants. Although several studies demonstrated that OS-resistant A(H1N1)pdm09 viruses are as virulent as their OS-sensitive virus counterparts,6,7 the viruses showed basically mild virulence in vivo. Here, the virulence potential of drug-resistant A(H1N1)pdm09 variants conferred by the H274Y mutation in the NA gene (CA04H274Y) was investigated, along with wild-type California/04/09 (CA04) virus in mice. Furthermore, to determine whether the CA04H274Y can become more virulent than its CA04 virus counterpart, parallel mouse adaptation of these OS-resistant and OS-sensitive parental strains was performed by serial lung-to-lung passage for five times. Both viruses were generated by reverse genetics and the H274Y mutation was given by site directed mutagenesis in CA04 virus. The research protocol for the use of mice in this study was in strict accordance and adherence with relevant policies regarding animal handling as mandated under the Guidelines for Animal Use and Care of the Korea Center for Disease Control.

Initially, 104.5 TCID50 in 30 µl were administered intranasally (i.n.) to groups of four BALB/c mice after light anesthesia with a mixture of Zoletil (VirBac) and Rompun (Bayer). Lungs from infected mice were collected 5 days (d) post-inoculation (p.i.), and the supernatant of the homogenate was administered to naïve mice for the subsequent four additional passages. Finally to compare pathogenicity, 104.0 TCID50 of the mouse-adapted viruses and their parental strains (maCA04_A–D and maCA04H274Y_A–D vs. CA04 and CA04H274Y, respectively), were administered in groups of five mice and were monitored for morbidity and mortality for 12 d p.i. If the infected mice lost more than 30% of their body weight, they were euthanized. Three of four independently passaged, mouse-adapted CA04 viruses (maCA04) were 100% lethal, but the other one had a 60% survival rate starting at 7 d p.i. (Fig. 1A and B). All 4 independently passaged, mouse-adapted CA04H274Y viruses (maCA04H274Y) killed all infected mice within 7 d p.i. (Fig. 1C and D). These findings show that the OS-resistant variants can cause mortality and morbidity equivalent to that of the mouse-adapted wild-type A(H1N1)pdm09 virus after serial lung-to-lung passages.

figure kvir-04-06-10925952-g001
Figure 1. Comparison and characterization of virulence between mouse-adapted and parental viruses in BALB/c mice. Five independent serial lung-to-lung passages for each virus (CA04 and CA04H274Y) were performed. After adaptation, 104.0 TCID50 ...

To confirm the genetic stability of the conferred H274Y mutation in the NA gene and examine whether any additional mutations occurred in the viral genome during adaptation, the whole genome sequences of 8 mouse-adapted viruses were analyzed and compared with their parental viruses. We found 10 amino acid substitutions in 6 genes of the 8 mouse-adapted viruses during adaptation (Table 1); one synonymous silent mutation (G1068C) was additionally noted within the corresponding H1 HA2 protein region of the maCA04 viruses (data not shown). The conferred H274Y mutation in the NA gene of the CA04H274Y virus was retained after mouse adaptation in all 4 independent parallel passages, showing that the OS resistance–inducing mutation did not create genetic instability or need other compensatory mutations in the NA gene to increase virulence. Three mutations (S183P and D222G in HA [H1 numbering] and D101G in NP) were almost synonymously found in our mouse-adapted CA04 (maCA04_A–C) and CA04H274Y (maCA04H274Y_A–D) viruses (Table 1), and were also correspondingly noted in previous mouse-adaptation studies.10-12 The maCA04_D virus did not kill all mice and retained the wild-type sequence of 222D in the HA gene (Fig. 1B and Table 1). The D222G mutation in HA gene has been associated with severe-to-fatal cases of human A(H1N1)pdm09 infections and lethal swine H1N2 virus infection in ferrets.14,15 Interestingly, all maCA04H274Y viruses, but not maCA04 viruses, acquired a synonymous K153E mutation in the HA gene, suggesting a potential association with the H274Y mutation. On the other hand, maCA04_C virus had further mutations in PB1 (N105T and R721K) and HA (K119E) while maCA04H724Y also incurred a S714R substitution in PB2. The E158G and T97I mutations found in PB2 and PA, respectively, of several mouse-adapted viruses in our study have been reported to be associated with increased polymerase activity or virulence.11,16,17

Table thumbnail
Table 1. Amino acid substitutions identified after mouse adaptation of pandemic H1N1 2009 and oseltamivir-resistant variants

For further characterization of the virulent phenotype of OS-resistant variants, maCA04H274Y_C and maCA04_A viruses, which only differ in HA153 (E or K, respectively) were plaque-purified and selected as described elsewhere,16 and tested for morbidity, mortality, and viral lung titer. Groups of 5 mice were inoculated i.n. with 103.0 TCID50 of the parental and plaque-purified mouse adapted viruses (CA04, CA04H274Y, maCA04, and maCA04H274Y) and monitored for survival and body weight loss daily for 12 d. Similar to the results of infection with the passaged viruses in lungs, mice infected with the plaque-purified mouse-adapted viruses (maCA04 and maCA04H274Y) had dramatic weight loss and succumbed to infection within 9 d p.i. (Fig. 1E and F) although maCA04H274Y killed all inoculated mice at 7 dpi. Viral replication kinetics in mouse lungs (n = 12) revealed that the mouse-adapted viruses yielded titers more than 10-fold higher than those of parental viruses at 1 and 3 d p.i., and no difference was observed between maCA04 and maCA04H274Y at any time, which implies that the adaptation of the OS-resistant H274Y variant in mice increased growth properties to as high as that of the wild-type virus in vivo (Fig. 1G). The increased yields of mouse-adapted viruses in mouse lungs was also observed in MDCK cells and eggs, which yielded significantly higher titers (>101.3-fold, P < 0.05) than their parental strains (Table 2). To determine the 50% mouse lethal dose (MLD50) of the viruses, we inoculated groups of 5 mice i.n. with 10-fold serial dilutions containing 101 to 105 TCID50 of the viruses. The maCA04 and maCA04H274Y viruses showed more than 103.5-fold higher MLD50 values,(2.0 and 1.5, respectively) than their parental viruses (>5.5 in both) (Table 2). Histopathologic analysis revealed that maCA04 and maCA04H274Y viruses caused more severe lung tissue damage than their parental strains because intraepithelial infiltration of neutrophils and macrophages resulted in acute bronchointerstitial pneumonia at 5 d p.i. (Fig. 1H–K).

Table thumbnail
Table 2. Characteristics of growth efficiency and virulence, and neuraminidase-inhibitor susceptibility of wild-type and mouse-adapted pandemic H1N1 influenza viruses and their oseltamivir-resistant counterpart

To determine whether the CA04H274Y variant and its adapted counterpart were resistant to NAIs, NA inhibition assays as described by Potieret al.18 were performed. Briefly, viruses were standardized to an NA activity 10-fold greater than that of the background and then incubated with serial 3-fold dilutions of drugs, including oseltamivir carboxylate (TRC Inc.), zanamivir (TRC Inc.), and peramivir (kindly provided by Green Cross Inc.). NA activity of viruses was determined using the NA-Star influenza NA inhibitor resistance detection kit (Applied Biosystems) according to the manufacturer’s instructions. Fifty percent inhibitory concentration (IC50) values were calculated using nonlinear curve fitting with GraphPad Prism software (GraphPad Software). If a mutant virus showed <5-fold increase in IC50 value over that of the wild-type virus, it was considered sensitive to NAIs. If a mutant virus showed >50-fold increase over the wild-type strain, it was considered highly resistant to NAIs. The IC50 values of CA04 and maCA04 viruses were sensitive to all the NAIs tested (Table 2). CA04H274Y, which showed high resistance to OS as well as peramivir, retained its low susceptibility to the two NAIs (149- and 169.4-fold in IC50, respectively) (Table 2). Collectively, the results showed that OS-resistant variants could increase virulence without losing resistance to NAIs as much as their OS-sensitive counterparts during adaptation in a new host and share a molecular basis of pathogenesis similar to that in the wild-type A(H1N1)pdm09 virus.

Here, we show that parental CA04 and CA04H274Y viruses had comparable replicative ability and virulence in mice which corresponded to previous studies.6,7 However, we also show for the first time that mammalian adaptation of the CA04H274Y virus through serial passage in mice resulted to increased growth properties and virulence in vitro and/or in vivo with no apparent alteration of NAI resistance implicating undiminished viral fitness conferred by the H274Y mutation. Increased in pathogenicity of CA04 and CA04H274Y viruses appeared to be associated with previously described specific mutations, particularly HA-D222G, as a consequence of mouse adaptation of indicating parallel genetic evolution of A(H1N1)pdm09 viruses despite differences in OS-sensitivities. Notably, infection with a A(H1N1)pdm09 containing both NA-H274Y and HA-D222G mutations demonstrated persistent viral replication and induced severe illness that culminated to death,19 indicating that combination of this two mutations in the context of the A(H1N1)pdm09 virus could be lethal. It is also noteworthy that only maCA04H274Y viruses additionally contained consensus K153E mutation in HA. The presence of HA-153E affects receptor binding specificity by decreasing affinity for both α-2-3- and α-2-6-sialic receptors.20,21 Given that the H274Y mutation also confers decreased NA enzymatic activity,22,23 it appears that the K153E mutation could be induced by the NA-H274Y to restore the balance between HA and NA activities. It is interesting to note that inoculation with maCA04H274Y containing HA-153E induced rapid weight loss and killed all infected mice two days earlier than maCA04 giving it merit for more in-depth study.

Regardless of these results, the lethal OS-resistant variant remained sensitive to zanamivir, which is an alternative influenza antiviral agent for the variant (Table 2). However, extensive selective pressure by NAIs could result in other variants that could acquire multidrug resistance, such as the I223R mutation which also showed viral fitness comparable to that of the wild type.24,25 Altogether, our findings emphasize the potential emergence of drug-resistant variants associated with high virulence as well as the need for the development of novel antiviral agents.

Submitted

Submitted

05/15/2013

Revised

Revised

07/24/2013

Accepted

Accepted

07/29/2013

Disclosure of Potential Conflicts of Interest

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

This work was supported by a grant from the Korea Healthcare Technology R&D Project (A103001) by the Ministry of Health and Welfare, Republic of Korea. We appreciate David Galloway for editorial assistance.

References

1. WHO. Influenza A virus resistance to oseltamivir and other antiviral medicines.,2009.
2. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, et al. . Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008; 52:3284 - 92; http://dx.doi.org/; PMID: 18625765 10.1128/AAC.00555-08 [PMC free article] [PubMed] [Cross Ref]
3. Ives JA, Carr JA, Mendel DB, Tai CY, Lambkin R, Kelly L, et al. . The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002; 55:307 - 17; http://dx.doi.org/; PMID: 12103431 10.1016/S0166-3542(02)00053-0 [PubMed] [Cross Ref]
4. Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009; 360:953 - 6; http://dx.doi.org/; PMID: 19258250 10.1056/NEJMp0900648 [PubMed] [Cross Ref]
5. Centers for Disease Control and Prevention (CDC). Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:969 - 72; PMID: 19745803 [PubMed]
6. Kiso M, Shinya K, Shimojima M, Takano R, Takahashi K, Katsura H, et al. . Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. PLoSPathog 2010; 6:e1001079; http://dx.doi.org/; PMID: 20865125 10.1371/journal.ppat.1001079 [PMC free article] [PubMed] [Cross Ref]
7. Hamelin ME, Baz M, Abed Y, Couture C, Joubert P, Beaulieu E, et al. . Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets. PLoSPathog 2010; 6:e1001015; http://dx.doi.org/; PMID: 20661429 10.1371/journal.ppat.1001015 [PMC free article] [PubMed] [Cross Ref]
8. Song MS, Lee JH, Pascua PN, Baek YH, Kwon HI, Park KJ, et al. . Evidence of human-to-swine transmission of the pandemic (H1N1) 2009 influenza virus in South Korea. J ClinMicrobiol 2010; 48:3204 - 11; http://dx.doi.org/; PMID: 20610681 10.1128/JCM.00053-10 [PMC free article] [PubMed] [Cross Ref]
9. Berhane Y, Ojkic D, Neufeld J, Leith M, Hisanaga T, Kehler H, et al. . Molecular characterization of pandemic H1N1 influenza viruses isolated from turkeys and pathogenicity of a human pH1N1 isolate in turkeys. Avian Dis 2010; 54:1275 - 85; http://dx.doi.org/; PMID: 21313850 10.1637/9422-061410-Reg.1 [PubMed] [Cross Ref]
10. Sakabe S, Ozawa M, Takano R, Iwastuki-Horimoto K, Kawaoka Y. Mutations in PA, NP, and HA of a pandemic (H1N1) 2009 influenza virus contribute to its adaptation to mice. Virus Res 2011; 158:124 - 9; http://dx.doi.org/; PMID: 21458512 10.1016/j.virusres.2011.03.022 [PMC free article] [PubMed] [Cross Ref]
11. Ilyushina NA, Khalenkov AM, Seiler JP, Forrest HL, Bovin NV, Marjuki H, et al. . Adaptation of pandemic H1N1 influenza viruses in mice. J Virol 2010; 84:8607 - 16; http://dx.doi.org/; PMID: 20592084 10.1128/JVI.00159-10 [PMC free article] [PubMed] [Cross Ref]
12. Ye J, Sorrell EM, Cai Y, Shao H, Xu K, Pena L, et al. . Variations in the hemagglutinin of the 2009 H1N1 pandemic virus: potential for strains with altered virulence phenotype?. PLoSPathog 2010; 6:e1001145; http://dx.doi.org/; PMID: 20976194 10.1371/journal.ppat.1001145 [PMC free article] [PubMed] [Cross Ref]
13. Who. Geneva: World Health Organisation; 2011. Update on oseltamivir resistance to influenza H1N1 (2009) viruses. 2012.
14. Pascua PN, Song MS, Lee JH, Baek YH, Kwon HI, Park SJ, et al. . Virulence and transmissibility of H1N2 influenza virus in ferrets imply the continuing threat of triple-reassortant swine viruses. ProcNatlAcadSci U S A 2012; 109:15900 - 5; http://dx.doi.org/; PMID: 23019374 10.1073/pnas.1205576109 [PubMed] [Cross Ref]
15. Rykkvin R, Kilander A, Dudman SG, Hungnes O. Within-patient emergence of the influenza A(H1N1)pdm09 HA1 222G variant and clear association with severe disease, Norway. Euro Surveill 2013; 18:18; PMID: 23351651 [PubMed]
16. Song MS, Pascua PN, Lee JH, Baek YH, Lee OJ, Kim CJ, et al. . The polymerase acidic protein gene of influenza a virus contributes to pathogenicity in a mouse model. J Virol 2009; 83:12325 - 35; http://dx.doi.org/; PMID: 19793828 10.1128/JVI.01373-09 [PMC free article] [PubMed] [Cross Ref]
17. Zhou B, Li Y, Halpin R, Hine E, Spiro DJ, Wentworth DE. PB2 residue 158 is a pathogenic determinant of pandemic H1N1 and H5 influenza a viruses in mice. J Virol 2011; 85:357 - 65; http://dx.doi.org/; PMID: 20962098 10.1128/JVI.01694-10 [PMC free article] [PubMed] [Cross Ref]
18. Potier M, Mameli L, Bélisle M, Dallaire L, Melançon SB. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. Anal Biochem 1979; 94:287 - 96; http://dx.doi.org/; PMID: 464297 10.1016/0003-2697(79)90362-2 [PubMed] [Cross Ref]
19. DeVries A, Wotton J, Lees C, Boxrud D, Uyeki T, Lynfield R. Neuraminidase H275Y and hemagglutinin D222G mutations in a fatal case of 2009 pandemic influenza A (H1N1) virus infection. Influenza Other Respi Viruses 2012; 6:e85 - 8; http://dx.doi.org/; PMID: 22243670 10.1111/j.1750-2659.2011.00329.x [PMC free article] [PubMed] [Cross Ref]
20. Rudneva I, Ignatieva A, Timofeeva T, Shilov A, Kushch A, Masalova O, et al. . Escape mutants of pandemic influenza A/H1N1 2009 virus: variations in antigenic specificity and receptor affinity of the hemagglutinin. Virus Res 2012; 166:61 - 7; http://dx.doi.org/; PMID: 22459010 10.1016/j.virusres.2012.03.003 [PubMed] [Cross Ref]
21. Soundararajan V, Tharakaraman K, Raman R, Raguram S, Shriver Z, Sasisekharan V, et al. . Extrapolating from sequence--the 2009 H1N1 ‘swine’ influenza virus. Nat Biotechnol 2009; 27:510 - 3; http://dx.doi.org/; PMID: 19513050 10.1038/nbt0609-510 [PubMed] [Cross Ref]
22. Duan S, Boltz DA, Seiler P, Li J, Bragstad K, Nielsen LP, et al. . Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoSPathog 2010; 6:e1001022; http://dx.doi.org/; PMID: 20686654 10.1371/journal.ppat.1001022 [PMC free article] [PubMed] [Cross Ref]
23. Pizzorno A, Bouhy X, Abed Y, Boivin G. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis 2011; 203:25 - 31; http://dx.doi.org/; PMID: 21148493 10.1093/infdis/jiq010 [PMC free article] [PubMed] [Cross Ref]
24. Eshaghi A, Patel SN, Sarabia A, Higgins RR, Savchenko A, Stojios PJ, et al. . Multidrug-resistant pandemic (H1N1) 2009 infection in immunocompetent child. Emerg Infect Dis 2011; 17:1472 - 4; PMID: 21801626 [PMC free article] [PubMed]
25. van der Vries E, Stelma FF, Boucher CA. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 2010; 363:1381 - 2; http://dx.doi.org/; PMID: 20879894 10.1056/NEJMc1003749 [PubMed] [Cross Ref]

Articles from Virulence are provided here courtesy of Taylor & Francis